STOCK TITAN
  1. Home
  2. Sec-filings
  3. DNLI
  4. [8-K] – Denali Therapeutics Inc. (DNLI) (CIK 0001714899)

[8-K] – Denali Therapeutics Inc. (DNLI) (CIK 0001714899)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock DNLI logo
Denali Therapeut

NASDAQ:DNLI

DNLI Rankings

#2033 Ranked by Market Cap
N/A Ranked by Dividends

DNLI Latest News

Oct 13, 2025
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
Aug 11, 2025
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Jul 7, 2025
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
May 6, 2025
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
Apr 2, 2025
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

DNLI Latest SEC Filings

Sep 5, 2025
[Form 4] Denali Therapeutics Inc. Insider Trading Activity
Aug 14, 2025
[Form 4] Denali Therapeutics Inc. Insider Trading Activity
Aug 14, 2025
[Form 4] Denali Therapeutics Inc. Insider Trading Activity
Aug 13, 2025
[144] Denali Therapeutics Inc. SEC Filing
Aug 12, 2025
[144] Denali Therapeutics Inc. SEC Filing

DNLI Stock Data

2.19B
131.85M
9.83%
96.25%
9.4%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO